MENU
+Compare
ALLO
Stock ticker: NASDAQ
AS OF
May 14, 04:59 PM (EDT)
Price
$0.93
Change
-$0.20 (-17.70%)
Capitalization
208.38M

ALLO Allogene Therapeutics Forecast, Technical & Fundamental Analysis

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases... Show more

Industry: #Biotechnology
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ALLO with price predictions
May 13, 2025

Momentum Indicator for ALLO turns negative, indicating new downward trend

ALLO saw its Momentum Indicator move below the 0 level on May 06, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In of the 87 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ALLO turned negative on May 07, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

ALLO moved below its 50-day moving average on May 05, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ALLO entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in of 245 cases, the price rose further within the following month. The odds of a continued upward trend are .

ALLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.641) is normal, around the industry mean (14.420). P/E Ratio (0.000) is within average values for comparable stocks, (65.047). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.146). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. ALLO's P/S Ratio (10000.000) is very high in comparison to the industry average of (254.920).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ALLO is expected to report earnings to rise 2.29% to -28 cents per share on May 13

Allogene Therapeutics ALLO Stock Earnings Reports
Q1'25
Est.
$-0.29
Q4'24
Beat
by $0.04
Q3'24
Beat
by $0.01
Q2'24
Est.
$-0.35
Q1'24
Beat
by $0.03
The last earnings report on March 13 showed earnings per share of -28 cents, beating the estimate of -31 cents. With 13.02M shares outstanding, the current market capitalization sits at 208.38M.
A.I. Advisor
published General Information

General Information

a developer of allogeneic chimeric antigen receptor therapy

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
233
Web
https://www.allogene.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AFGFX75.87N/A
N/A
Virtus Silvant Focused Growth R6
RYLIX95.20N/A
N/A
Rydex Leisure Inv
DCINX17.04N/A
N/A
Dunham International Stock C
LCORX21.70N/A
N/A
Leuthold Core Investment Retail
SVBAX28.77N/A
N/A
JHancock Balanced A

ALLO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with CRSP. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
-3.42%
CRSP - ALLO
61%
Loosely correlated
+4.49%
FATE - ALLO
57%
Loosely correlated
-6.54%
NTLA - ALLO
57%
Loosely correlated
-2.69%
PRME - ALLO
53%
Loosely correlated
-5.22%
BEAM - ALLO
53%
Loosely correlated
-1.04%
More